Mutual of America Capital Management LLC Sells 12,613 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Mutual of America Capital Management LLC trimmed its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 7.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 154,166 shares of the biotechnology company’s stock after selling 12,613 shares during the quarter. Mutual of America Capital Management LLC owned approximately 0.05% of Exelixis worth $4,001,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in EXEL. Seizert Capital Partners LLC grew its stake in shares of Exelixis by 8.0% during the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after purchasing an additional 34,875 shares during the last quarter. Natixis Advisors LLC grew its stake in shares of Exelixis by 26.2% during the third quarter. Natixis Advisors LLC now owns 29,113 shares of the biotechnology company’s stock valued at $755,000 after purchasing an additional 6,051 shares during the last quarter. CIBC Asset Management Inc bought a new stake in shares of Exelixis during the third quarter valued at approximately $227,000. Buck Wealth Strategies LLC bought a new stake in shares of Exelixis during the third quarter valued at approximately $221,000. Finally, Victory Capital Management Inc. grew its stake in shares of Exelixis by 16.6% during the third quarter. Victory Capital Management Inc. now owns 136,178 shares of the biotechnology company’s stock valued at $3,534,000 after purchasing an additional 19,372 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 41,588 shares of Exelixis stock in a transaction on Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the sale, the executive vice president now directly owns 288,665 shares in the company, valued at approximately $9,918,529.40. The trade was a 12.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Dana Aftab sold 1,162 shares of Exelixis stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at approximately $15,666,873. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 289,736 shares of company stock worth $9,471,510 over the last ninety days. Company insiders own 2.85% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on EXEL. BMO Capital Markets increased their price target on shares of Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JMP Securities reaffirmed a “market outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Friday, October 11th. Bank of America raised their price objective on shares of Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Stephens raised their price objective on shares of Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $31.44.

Exelixis Stock Up 0.5 %

Shares of NASDAQ:EXEL opened at $34.83 on Friday. Exelixis, Inc. has a 12 month low of $19.20 and a 12 month high of $36.60. The company’s fifty day simple moving average is $29.72 and its 200 day simple moving average is $25.48. The firm has a market cap of $9.95 billion, a price-to-earnings ratio of 22.33, a PEG ratio of 0.87 and a beta of 0.51.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. During the same period last year, the business posted $0.10 earnings per share. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. Research analysts expect that Exelixis, Inc. will post 1.68 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.